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Abstract. Background: Distinct populations of neutrophils
have been identified based on the expression of inter-
cellular adhesion molecule 1 (ICAM1, CD54) and
chemokine receptor 1 (CXCR1, interleukin 8 receptor α).
Aim: We analyzed the expression of vascular endothelial
growth factor receptor 1 (VEGFR1), a physiological
negative regulator of angiogenesis, on distinct populations
of neutrophils from the blood of patients before and after
adjuvant chemotherapy for breast cancer. Materials and
Methods: Neutrophil populations were distinguished as
reverse transmigrated (ICAM1high/CXCR1low), naïve
(ICAM1low/CXCR1high), or tissue-resident neutrophils
(ICAM1low/CXCR1low), and their VEGFR1 expression
quantified. Results: Reverse transmigrated ICAM1high/
CXCR1low neutrophilic granulocytes decreased significantly
after chemotherapy and these were also the cells with
highest mean fluorescence intensity for VEGFR1.
Conclusion: Chemotherapy mainly reduces the number of
reverse transmigrated long-lived ICAM1high/CXCR1low
VEGFR1-expressing neutrophils. The decrease of
antiangiogenic VEGFR1 may have a potential impact on
tumour angiogenesis in patients undergoing adjuvant
chemotherapy.
Neutrophilic granulocytes constitute the most abundant sub-
population of leukocytes in peripheral blood. Neutrophilic
granulocyte count is very dynamic and it has been known for
a long time that secondary agranulocytosis or neutropenia
arises after cytotoxic chemotherapy due to impaired
proliferation in bone marrow, with subsequent recovery
depending on the dose of chemotherapy given (1). Maturation
and expression of surface antigens of granulocytes are studied
much less than other hematopoietic cells, and only for a
limited spectrum of diseases (2). Early studies of granulocytic
surface antigens focused on the diagnosis of certain inherited
disorders, such as leukocyte adhesion molecule deficiency, in
which a specific antigen is known to be missing (3). 
Recent studies have demonstrated that neutrophils are not a
homogenous population of cells. Phenotypically and
functionally distinct populations of neutrophils have been
identified based on the expression of intercellular adhesion
molecule 1 (ICAM1, CD54) and chemokine receptor 1
(CXCR1, interleukin 8 receptor α) in healthy volunteers and
patients with chronic inflammatory disease. Neutrophil sub-
populations can be divided into three groups based on their
expression of ICAM1 and CXCR1: reverse transmigrated
(ICAM1high/CXCR1low); naïve, ICAM1low/CXCR1high; and
tissue-resident (ICAM1low/CXCR1low) granulocytes (4).
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Vascular endothelial growth factor receptor 1 (VEGFR1)
is a physiological inhibitor of angiogenesis which is also
expressed on neutrophils (5, 6). We have recently shown that
after autologous stem cell transplantation a patient’s serum
elicits a strong antiangiogenic response, likely due to
neutrophil-derived antiangiogenic-soluble VEGFR1 within
the leucapheresis product, which may contribute to the
therapeutic efficacy of the transplantation (7).
For macrophages, it has been shown that expression of
VEGFR1 depends on the activation status and maturation of
the cell, with resting monocytes expressing only low levels
of VEGFR1 (8). In analogy to similar findings in monocytes,
VEGF-dependent neutrophil migration has been
demonstrated to be mediated by VEGFR1 (5). However, it is
not known if the expression of VEGFR1 in neutrophils also
depends on the activation status and maturation of the cell,
similarly to monocytes.
Differently from monocytes, neutrophils are especially
sensitive to external perturbations and can be easily activated
by the isolation process itself (9). In addition, the life-span of
neutrophils in vitro is short (10), making it logistically
almost impossible to study neutrophils in vitro (11). Given
the dynamics of neutrophilic granulocytes in peripheral
blood after chemotherapy, and neutrophilic granulocytes
being a source of antiangiogenic VEGFR1, an understanding
of how VEGFR1 expression is regulated as a function of the
distinct neutrophilic granulocyte populations would be of
interest. In addition, the effect of chemotherapy on
neutrophil decrease and recovery in vivo could be generally
exploited to overcome the limitations of cell culture and
artificial stimulation and maturation of neutrophilic
granuolocytes in vitro.
The aim of our study was to analyze the expression of
VEGFR1 on subpopulations of neutrophils depending on the
expression of ICAM1 and CXCR1 in the blood of patients
before and after adjuvant chemotherapy for early-stage breast
cancer.
Materials and Methods
Patients, blood samples, and isolation of leukocytes. Patients
undergoing adjuvant chemotherapy after operation for localised
breast cancer were included in the study. The study protocol was
approved by the local Ethics Commission (University of Zurich
approval number EK-1363) and written informed consent was
obtained from all patients. Patients’ characteristics are shown in
Table I. EDTA plasma (10 ml) and heparinised blood (20 ml)
samples were obtained before the first cycle of adjuvant
chemotherapy, and approximately 10 days later at the time when
patients attended for nadir determinations. Due to low recruitment
and logistic reasons, these rules were later expanded and patients
were included at any cycle of adjuvant chemotherapy. Leukocytes
were harvested after centrifugation of 20 ml heparinised blood at
400 ×g for 30 min at room temperature.
Analysis of full blood counts. Full blood counts from EDTA blood
samples were analysed and leucocyte subfractions quantified using
an automated blood cell analyser (ADVIA 120; Siemens,
Erlangen, Germany).
Flow cytometric analysis for ICAM1, CXCR1, and VEGFR1 expression
on granulocytes. Isolated leukocytes were incubated in 25 μl of FACS
buffer (FB; phosphate buffered saline, 5% fetal bovine serum, 0.1%
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Table I. Patients’ characteristics and time of blood analysis.
Total number of patients 15
Median age, years 44 (range=32 to 72)
Histology Invasive ductal carcinoma 10 (67%)
Invasive lobular carcinoma 5 (33%)
Tumor stage T1 3 (20%)
T2 9 (60%)
T3 3 (20%)
Nodal stage Negative 3 (20%)
Positive 12 (80%)
ER/PR status Positive 12 (80%)
Negative 3 (20%)
HER2 status Positive 3 (20%)
Negative 12 (80%)
ER/PR/HER2-negative 3 (20%)
Chemotherapy regimen Doxorubicin/cyclophosphamide-paclitaxel 9 (60%)
5-Fluorouracil/epirubicin/cyclophosphamide 5 (33%)
Paclitaxel/carboplatin 1 (7%)
Blood analysis before/after First cycle of chemotherapy 6 (40%)
> First cycle of chemotherapy 9 (60%)
Median time of blood analysis, days 
Before chemotherapy 0 (range=−4 to 0)
After chemotherapy 10 (range=7 to 54)
sodium azide) with an allophycocyanin (APC)-labelled monoclonal
mouse antibody to human VEGFR1 (R&D Systems, Abingdon,
Oxford, UK), followed by incubation with a fluorescein isothiocyanate
(FITC)-labelled mouse antibody to human CXCR1 (CD181) (BD
Biosciences-Pharmingen, San Diego, CA, USA) and a phycoerythrin
(PE)-labelled mouse antibody to human ICAM1 (CD54) (BD
Biosciences-Pharmingen). As a control for the scatter pattern of
neutrophilic granulocytes, an aliquot of leukocytes incubated with
mouse antibody to human VEGFR1 were incubated with a FITC-
labelled mouse antibody to human CD16 (BD Biosciences-
Pharmingen). After incubation for 20 min at 4˚C in the dark, leukocytes
were washed once with 2 ml FB, then 1 ml FACS lysing solution (BD
Biosciences-Pharmingen) was added to lyse erythrocytes and fix the
cells. When a clear solution was reached (3-5 min), cells were washed
with 2 ml FB, resuspended in 300 μl FB, and subjected to flow
cytometry. Flow cytometry was performed using a FACSCalibur® flow
cytometer running with CellQuestPro software (Becton Dickinson
Biosciences, Franklin Lakes, NJ, USA). Neutrophilic granulocytes were
first identified according to their typical light-scattering pattern (12),
then divided into three groups dependent upon their expression of
ICAM1 and CXCR1: reverse transmigrated, ICAM1high/CXCR1low;
naïve, ICAM1low/CXCR1high; and tissue-resident, ICAM1low/
CXCR1low. Each of the three different subgroups was further analysed
according to the mean fluorescence intensity (MFI) of VEGFR1, using
FlowJo software (Tree Star, Inc., Ashland, OR, USA).
Quantification of VEGFR1 protein expression by enzyme-linked
immunosorbent assay (ELISA). ELISA for the quantification of
VEGFR1 was performed using the immunoassay from R&D Systems
(Abingdon, Oxford, UK) according to the manufacturer’s instructions.
VEGFR1 concentrations in EDTA-plasma were expressed in pg/ml.
Statistics. The non-parametric Wilcoxon signed rank and Mann
Whitney U-tests were applied to determine statistical significance
of the difference between two groups for paired, and unpaired data,
respectively. A value of p<0.05 was considered significant.
Results
Blood samples from 15 patients undergoing adjuvant
chemotherapy for breast cancer were analyzed in this study.
For six patients, blood samples were taken before and after
the first cycle of chemotherapy, nine patients were more
advanced in their chemotherapy cycles. The median time of
blood sampling was 0 (range=4-0) days before, and 10
(range=7-54) days after chemotherapy. Patients’
characteristics are shown in Table I. Table II summarizes the
results of neutrophilic granulocyte analysis. Automated blood
cell analysis showed that neutrophilic granulocyte counts
dropped by 66.5% (median) after chemotherapy, from 3.28
to 1.1 cells/nl, however, this change was not statistically
significant (Figure 1a). FACS analysis of neutrophilic
granulocytes demonstrated that MFI of VEGFR1 did not
change significantly after chemotherapy (Figure 1b).
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Figure 1. Neutrophilic granulocyte counts (a), vascular endothelial growth factor receptor 1 (VEGFR1) mean fluorescence intensity (MFI) of neutrophilic
granulocytes (b), and VEGFR1 plasma concentrations (c) of patients before and 12 days (median) after adjuvant chemotherapy for breast cancer
(n=15). Neutrophilic granulocyte counts dropped by 66.5% from 3.28 to 1.1 per nl; this change is not statistically significant (a). Flow cytometric
analysis of neutrophilic granulocytes demonstrated that VEGFR1 MFI did not change significantly (b). Median VEGFR1 plasma concentration did not
change significantly (170.44 vs. 171.76 pg/ml), but there was a high variation of individual changes, ranging from 77% to +914% (c).
ELISA of patient EDTA-treated plasma showed that the
median VEGFR1 concentration did not change significantly
(170.4 before vs. 171.76 pg/ml after chemotherapy).
However, there was a high variation between individual
changes, ranging from −77% to 914% (Figure 1c).
FACS characterisation of neutrophilic granulocytes from
blood of patients before and at a median of 10 days after
adjuvant chemotherapy for breast cancer, based on the
expression of ICAM1, CXCR1 and VEGFR1, showed that
reverse transmigrated neutrophilic granulocytes decreased
significantly after chemotherapy from 98 to 31/μl. The decrease
in naïve and in tissue-resident phenotype neutrophilic
granulocytes (from 1871 to 555, and 485 to 179/μl,
respectively) was not statistically significant (Figure 2a).
Of note, VEGFR1 expression levels were significantly
different between the three neutrophilic granulocyte
populations, with the MFI being highest for reverse
transmigrated neutrophils, followed by tissue-resident, and
naïve neutrophilic granulocytes. The MFIs of all three
neutrophilic granulocyte populations did not change
significantly after chemotherapy and the significant
difference in MFI between the three neutrophilic granulocyte
populations was maintained (Figure 2b).
An example of FACS characterisation of neutrophilic
granulocytes, depending on the scatter pattern (cell size and
complexity), expression of ICAM1, CXCR1, and VEGFR1,
from a patient before and after adjuvant chemotherapy for
breast cancer is shown in Figure 3.
Discussion
Only little is known about the expression of VEGFR1 in
neutrophils in relation to activation status and maturation of
the cell. Buckley et al. identified a subset of human
neutrophils with a distinct profile of cell-surface receptors
which represent cells that have migrated through an
endothelial monolayer and then re-emerged by reverse
transmigration (ICAM1high/CXCR1low). These neutrophils
were rescued from apoptosis, demonstrated functional
priming, and were rheologically distinct from neutrophils that
had not undergone transendothelial migration, such as naïve
circulatory neutrophils and tissue-resident neutrophils (4).
In this study, we analyzed the expression of VEGFR1 on
sub-populations of neutrophils depending on the expression
of ICAM1 and CXCR1 in the blood of patients before and
after adjuvant chemotherapy for early-stage breast cancer.
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Figure 2. Fluorescence-activated cell sorting (FACS) characterisation of neutrophilic granulocytes from blood of patients (n=15) before and 10
days (median) after adjuvant chemotherapy for breast cancer based on the expression of inter-cellular adhesion molecule 1 (ICAM1, CD54),
chemokine receptor 1 (CXCR1, interleukin 8 receptor α), and vascular endothelial growth factor receptor 1 (VEGFR1). Reverse transmigrated
ICAM1high/CXCR1low neutrophilic granulocytes decreased significantly after chemotherapy from 98 to 31/μl. The decrease in naïve
ICAM1low/CXCR1high and in tissue-resident ICAM1low/CXCR1low neutrophilic granulocytes (from 1871 to 555, and 485 to 179/μl, respectively)
were not statistically significant (a). Mean fluorescence intensity (MFI) of VEGFR1 was significantly different for the three neutrophilic granulocyte
populations, with highest units for reverse transmigrated neutrophils, followed by tissue-resident, and naïve neutrophilic granulocytes. The MFIs of
all three neutrophilic granulocyte populations did not change significantly after chemotherapy and the significantly different MFIs between the three
neutrophilic granulocyte populations were maintained (b). *p<0.05. p<0.05 (reverse transmigrated vs. naïve, and vs. tissue-resident and naïve vs.
tissue-resident neutrophilic granulocytes, respectively) †before, and ‡after chemotherapy, respectively.
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Figure 3. Example of fluorescence-activated cell sorting (FACS) characterisation of neutrophilic granulocytes, depending on the scatter pattern (cell
size and complexity), expression of inter-cellular adhesion molecule 1 (ICAM1, CD54), chemokine receptor 1 (CXCR1, interleukin 8 receptor α), and
vascular endothelial growth factor receptor 1 (VEGFR1) of a patient before (a,b,c) and after (d,e,f) adjuvant chemotherapy for breast cancer (pT2
pN1, estrogen receptor/progesterone receptor-positive, HER2-negative invasive-lobular carcinoma). Blood was taken on the day of, and 15 days
after chemotherapy, respectively (1st cycle doxorubicin/cyclophosphamide). Neutrophilic granulocyte count after chemotherapy (a, d) and proportion
of reverse transmigrated ICAM1high/CXCR1low neutrophilic granulocytes after chemotherapy (b, e). Mean fluorescence intensity (MFI) of VEGFR1
in the three types of neutrophilic granulocytes before and after chemotherapy (c, f).
Table II. Median neutrophilic granulocyte count, mean fluorescence intensity (MFI) of vascular endothelial growth factor receptor 1 (VEGFR1),
and plasma VEGFR1 concentration before and after adjuvant chemotherapy for breast cancer.
Chemotherapy Change (%) p-Value*
Before After
Median count (range) (×103/ul)
Neutrophilic granulocytes 3.28 (1.56-7.65) 1.10 (0.15-19.4) −66.5 0.11
Reverse transmigrated 0.098 (0.021-0.895) 0.031 (0.002-0.359) −68.1 0.031
Naïve 1.871 (0.501-7.153) 0.555 (0.096-7.954) −70.3 0.46
Tissue-resident 0.485 (0.045-2.701) 0.179 (0.008-6.693) −63.0 0.16
Median (range) MFI of VEGFR1
Neutrophilic granulocytes 3.69 (0.02-0.43) 4.77 (0.00-1.63) 29.3 0.51
Reverse transmigrated 5.720 (0.078-0.504) 6.250 (0.017-1.853) 9.3 0.22
Naïve 3.960 (0.048-0.837) 3.790 (0.005-2.153) −4.3 0.46
Tissue-resident 4.660 (0.057-0.414) 4.800 (0.016-2.406) 3.0 0.14
Median (range) plasma VEGFR1 (pg/ml) 170.4 (30.8-586.1) 171.76 (33.4-537.3) 0.8 0.75
Reverse transmigrated: Inter-cellular adhesion molecule 1 (ICAM1)high/chemokine receptor 1 (CXCR1)low; naïve : ICAM1low/CXCR1high; tissue-
resident: ICAM1low/CXCR1low. *Wilcoxon signed rank test.
Reverse transmigrated neutrophilic granulocytes decreased
significantly after chemotherapy. The decrease in naïve and
tissue-resident neutrophilic granulocytes were not statistically
significant. The percentage of reverse transmigrated
neutrophilic granulocytes in our study was comparable with
the one found by Buckley et al. (i.e. 0.25% in healthy donors
and 1-2% in patients with systemic inflammation (4)).
VEGFR1 expression levels were significantly different
between the three neutrophilic granulocyte populations, with
highest MFI for reverse transmigrated neutrophils, followed
by tissue resident, and naïve neutrophilic granulocytes. This
pattern was retained as the MFIs of all three neutrophilic
granulocyte populations did not change significantly after
chemotherapy. This finding suggests that VEGFR1 expression
by neutrophilic granulocytes may follow the same pattern as
monocytes, since naïve neutrophilic granulocytes seem to
express VEGFR1 less intensely than the more mature,
activated tissue resident and transmigrated neutrophilic
granulocytes, as shown for monocytes previously.
These differences could be explained by the fact that
granulocytes have intracytoplasmic storage pools of numerous
surface antigens that can be translocated to the surface following
granulocytic activation or excessive manipulation (13). Given
the abundance of VEGFR1 expression on neutrophilic
granulocytes of leukapheresis products (7), which seems higher
than seen in this study, one might speculate if the mechanically
excessive manipulation of neutrophilic granulocytes (and other
blood cells) during the collection of bone marrow-derived stem
cells from peripheral blood, involving vigorous centrifugation,
might induce a stress response and trigger VEGFR1 expression.
However, the subpopulation of reverse transmigrated
neutrophilic granulocytes is also the smallest, and therefore it
seems unlike that the difference might result in biological
relevant changes in VEGFR1 density. 
Overall, MFI of VEGFR1 of neutrophilic granulocytes did
not change significantly. Similarly, serum VEGFR1
concentrations did not change significantly, although there
was a high variation between individual changes, ranging
from −77% to 914%.
VEGFR1 is not only expressed on neutrophils (5, 6), but
also on other cell types such as tumor cells (14), bone marrow-
derived progenitor cells (15), monocytes/ macrophages (8),
basophils (16), and platelets (17). Several different isoforms of
VEGFR1 are known to arise through alternative splicing:
classically, a full-length transmembrane protein, containing an
intracellular tyrosine kinase domain, is distinguished from a
truncated soluble form, lacking the transmembrane and tyrosine
kinase domains (sVEGFR1, also known as sFLT1) (18-22).
However, evidence is emerging that proteolytic cleavage of
VEGFR1 may also be involved in the generation of sVEGFR
(23, 24). VEGFR1 and sVEGFR1 both exert antiangiogenic
effects by sequestration of VEGF, and by forming heterodimers
with VEGFR1 and -2, respectively (25, 26).
We have previously shown that in neutrophilic granulocytes
undergoing massive manipulation during apheresis for stem
cell collection, VEGFR1 mRNA expression is shifted towards
the soluble isoform, sVEGFR1 (7). However, the
sVEGFR1:VEGFR1 ratio of unprocessed neutrophilic
granulocytes is not known. The fact that plasma concentrations
of sVEGFR1 are not different after chemotherapy in this study
are in line with the finding that overall MFI of VEGFR1 of
neutrophilic granulocytes is also unchanged. However, one
should bear in mind that the expression of VEGFR1 of
endothelial cells, for example, is one order of magnitude
higher (7) and thus the main source of sVEGFR1 in plasma
might not necessarily be neutrophilic granulocytes.
There are several limitations affecting this study: the
relatively small number of patients and especially the
inconsistency of therapy cycles and heterogeneity of
chemotherapy regimens may have affected the results. In
further studies, one should therefore stratify for the type of
substances used for chemotherapy and for patients with
significant neutropenia. Multiple measurements over time
would allow kinetics of changes to be seen. Given the
sometimes large individual variations of parameter changes
seen in this study, there may still be unknown factors
influencing dynamics of VEGFR1-expressing subpopulations
of neutrophilic granulocytes.
In summary, subpopulations of neutrophilic granulocytes
in patients before adjuvant chemotherapy for breast cancer
have similar distribution patterns to those previously reported
for healthy donors and patients with systemic inflammation
(4). Chemotherapy alters this distribution, with the
population of reverse transmigrated neutrophilic granulocytes
being significantly reduced; this is also the subpopulation
with the highest MFI for VEGFR1. However, reverse
transmigrated neutrophilic granulocytes only account for a
very small subpopulation of neutrophilic granulocytes and
consequently, expression and plasma concentration of
VEGFR1 do not change significantly after chemotherapy.
Studies including more homogenous patient populations
and consistent treatment regimens should further investigate
the potential impact on angiogenesis of decreasing numbers
of neutrophils expressing antiangiogenic VEGFR1 after
chemotherapy. 
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